Cephalosporins for uncomplicated skin and skin structure infections in emerging community-acquired MRSA

Bibliography

• HEROLD BC, IMMERGLUCK LC, MARANAN MC et al.: Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA (1998) 279:593-598.
   PubMed Web of Science ®Google Scholar
• NAIMI TS, LEDELL KH, COMO-SABETTI K et al.: Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA (2003) 290:2796-2784.
   Web of Science ®Google Scholar
• BORER A, GILAD J, YAGUPSKY P et al.: Community-acquired methicillin-resistant Staphylococcus aureus in institutionalized adults with developmental disabilities. Emerg. Infect. Dis. (2000) 8:966-970.
   Web of Science ®Google Scholar
• CHAMBERS HF: The changing epidemiology of Staphylococcus aureus? Emerg. Infect. Dis. (2001) 7:178-182.
   PubMed Web of Science ®Google Scholar
• GRAFFUNDER EM, VENEZIA RA: Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials. J. Antimicrob. Chemother. (2002) 49:999-1005.
   PubMed Web of Science ®Google Scholar
• SALGADO CD, FARR BM, CALFEE DP: Community-acquired methicillin-resistant Staphylococcus aureus: a meta-analysis of prevalence and risk factors. Clin. Infect. Dis. (2003) 36:131-139.
   PubMed Web of Science ®Google Scholar
• FRIDKIN SK, HAGEMAN JC, MORRISON M et al.: Methicillin-resistant Staphylococcus aureus disease in three communities. N. Engl. J. Med. (2005) 352:1436-1444.
   PubMed Web of Science ®Google Scholar
• CREECH CB II, KERNODLE DS, ALSENTZER A, WILSON C, EDWARDS KM: Increasing rates of nasal carriage of methicillin-resistant Staphylococcus aureus in healthy children. Pediatr. Infect. Dis. J. (2005) 24:617-621.
   PubMed Web of Science ®Google Scholar
• SATTLER CA, MASON EO Jr, KAPLAN SL: Prospective comparison of risk factors and demographic and clinical characteristics of community-acquired, methicillin-resistant versus methicilllin-susceptible Staphylococcus infection in children. Pediatr. Infect. Dis. J. (2002) 21:910-917.
   PubMed Web of Science ®Google Scholar
• CHAMBERS HF: Community-associated MRSA – resistance and virulence converge. N. Engl. J. Med. (2005) 352:1485-1487.
   PubMed Web of Science ®Google Scholar
• HEDRICK J: Acute bacterial skin infections in pediatric medicine: current issues in presentation and treatment. Paediatr. Drugs (2003) 5(Suppl. 1):35-46.
   PubMedGoogle Scholar
• DIEKEMA D, PFALLER M, SCHMITZ FJ et al.: Survey of infections due to Staphylococcal species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin. Infect. Dis. (2001) 32(Suppl. 2):S114-S132.
   PubMed Web of Science ®Google Scholar
• FRAZEE BW, LYNN J, CHARLEBOIS ED, LAMBERT L, LOWERY D, PERDREAU-REMINGTON F: High prevalence of methicillin-resistant Staphylococcus aureus in emergency department skin and soft tissue infections. Ann. Emerg. Med. (2005) 45:311-320.
   PubMed Web of Science ®Google Scholar
• MILLER LG, PERDREAU-REMINGTON F, RIEG G et al.: Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N. Engl. J. Med. (2005) 352:1445-1453.
   PubMed Web of Science ®Google Scholar
• SCHER RK, ELSTON DM, HEDRICK JA, JOSEPH WS, MAURER T, MURAKAWA GJ: Treatment options in the management of uncomplicated skin and skin structure infections. Cutis (2005) 75(Suppl. 1):3-23.
   PubMed Web of Science ®Google Scholar
• SADER HS, STREIT JM, FRITSCHE TR et al.: Potency and spectrum reevaluation of cefdinir tested against pathogens causing skin and soft tissue infections: a sample of North American isolates. Diagn. Microbiol. Infect. Dis. (2004) 49:283-287.
   PubMed Web of Science ®Google Scholar
• CHATTERJEE A, MOLAND ES, THOMSON KS: Cefdinir: an oral alternative to parenteral cephems. Diagn. Microbiol. Infect. Dis. (2005) 51:259-264.
   PubMed Web of Science ®Google Scholar
• VON EIFF C, FRIEDRICH AW, BECKER K, PETERS G: Comparative in vitro activity of ceftobiprole against staphylococci displaying normal and small-colony variant phenotypes. Antimicrob. Agents Chemother. (2005) 49:4372-4374.
   PubMed Web of Science ®Google Scholar
• PRESTON DA, TURIK M: Cefaclor: a contemporary look at susceptibility of key pathogens from around the globe. J. Chemother. (1998) 10:195-202.
   PubMed Web of Science ®Google Scholar
• JONES ME, KARLOWSKY JA, DRAGHI DC, THORNSBERRY C, SAHM DF, BRADLEY JS: Rates of antimicrobial resistance among common bacterial pathogens causing respiratory, blood, urine, and skin and soft tissue infections in pediatric patients. Eur. J. Clin. Microbiol. Infect. Dis. (2004) 23:445-455.
   PubMed Web of Science ®Google Scholar
• LADHANI S, GARBASH M: Staphylococcal skin infections in children: rational drug therapy recommendations. Paediatr. Drugs (2005) 7:77-102.
   PubMedGoogle Scholar
• JONES ME, KARLOWSKY JA, DRAGHI DC, THORNSBERRY C, SAHM DF, NATHWANI D: Epidemiology and antibiotic susceptibility of bacteria causing skin and soft tissue infections in the USA and Europe: a guide to appropriate antimicrobial therapy. Int. J. Antimicrob. Agents (2003) 22:406-419.
   PubMed Web of Science ®Google Scholar
• HOLAS C, CHIU YL, NOTARIO G, KAPRAL D: A pooled analysis of seven randomized crossover studies of the palatability of cefdinir oral suspension versus amoxicillin/clavulanate potassium, cefprozil, azithromycin, and amoxicillin in children aged 4 to 8 years. Clin. Ther. (2005) 27:1950-1960.
   PubMed Web of Science ®Google Scholar
• WELLINGTON K, CURRAN MP: Cefditoren pivoxil: a review of its use in the treatment of bacterial infections. Drugs (2004) 64:2597-2618.
   PubMed Web of Science ®Google Scholar
• GLINKA TW: Novel cephalosporins for the treatment of MRSA infections. Curr. Opin. Investig. Drugs (2002) 3:206-217.
   PubMedGoogle Scholar
• CHAMBERS HF: Ceftobiprole: in vivo profile of a bactericidal cephalosporin. Clin. Microbiol. Infect. (2006) 12(Suppl. 2):17-22.
   PubMed Web of Science ®Google Scholar
• HEBEISEN P, HEINZE-KRAUSS I, ANGEHRN P, HOHL P, PAGE MG, THEN RL: In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci. Antimicrob. Agents Chemother. (2001) 45:825-836.
   PubMed Web of Science ®Google Scholar
• ENTENZA JM, HOHL P, HEINZE-KRAUSS I, GLAUSER MP, MOREILLON P: BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis. Antimicrob. Agents Chemother. (2002) 46:171-177.
   PubMed Web of Science ®Google Scholar
• FUDA C, HESEK D, LEE M et al.: Mechanistic basis for the action of new cephalosporin antibiotics effective against methicillin-and vancomycin-resistant Staphylococcus aureus. J. Biol. Chem. (2006) 281:10035-10041.
   PubMed Web of Science ®Google Scholar
• STEVENS DL, BISNO AL, CHAMBERS HF et al.: Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin. Infect. Dis. (2005) 41:1373-1406.
   PubMed Web of Science ®Google Scholar
• TACK KJ, KEYSERLING CH, MCCARTHY J, HEDRICK JA: Study of use of cefdinir versus cephalexin for treatment of skin infections in pediatric patients. The Cefdinir Pediatric Skin Infection Study Group. Antimicrob. Agents Chemother. (1997) 41:739-742.
   PubMed Web of Science ®Google Scholar
• TACK KJ, LITTLEJOHN TW, MAILLOUX G, WOLF MM, KEYSERLING CH: Cefdinir versus cephalexin for the treatment of skin and skin-structure infections. The Cefdinir Adult Skin Infection Study Group. Clin. Ther. (1998) 20:244-256.
   PubMed Web of Science ®Google Scholar
• BUCKO AD, HUNT BJ, KIDD SL, HOM R: Randomized, double-blind, multicenter comparison of oral cefditoren 200 or 400 mg BID with either cefuroxime 250 mg BID or cefadroxil 500 mg BID for the treatment of uncomplicated skin and skin-structure infections. Clin. Ther. (2002) 24:1134-1147.
   PubMed Web of Science ®Google Scholar
• DEL ROSSO JQ: Cephalosporin therapy in the management of uncomplicated skin and soft tissue infections: focus on clinical applications and dosing schedules with oral cefdinir. Summer Meeting of the American Academy of Dermatology – 28 July - 1 August, New York, NY, USA (2004). Poster.
   Google Scholar
• ROSEN T: Update on treating uncomplicated skin and skin structure infections. J. Drugs Dermatol. (2005) 4(Suppl. 6):S9-S14.
   Google Scholar
• PICHICHERO MF: A review of evidence supporting the American Academy of Pediatrics recommendation for prescribing cephalosporin antibiotics for penicillin-allergic patients. Pediatrics (2005) 115:1048-1057.
   PubMed Web of Science ®Google Scholar